Sernova Corp.  

(Public, CVE:SVA)   Watch this stock  
Find more results for SVA
0.180
-0.005 (-2.70%)
May 22 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.18 - 0.18
52 week 0.12 - 0.29
Open 0.18
Vol / Avg. 25,000.00/149,310.00
Mkt cap 23.67M
P/E     -
Div/yield     -
EPS -0.02
Shares 129.64M
Beta 1.09
Inst. own     -

Key stats and ratios

Q1 (Jan '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -68.88% -53.50%
Return on average equity -72.68% -56.04%
CDP Score - -

Address

700 Collip Cir Suite 114
LONDON, ON N6G 4X8
Canada
+1-519-8585184 (Phone)
+1-519-8585099 (Fax)

Website links

Description

Sernova Corp. is a Canada-based clinical-stage company, which is engaged in developing products for the treatment of chronic debilitating diseases using the Cell Pouch system. The Company’s technologies include Cell Pouch System and Sertolin Technology. Cell Pouch System is implantable and scalable medical device. Sertolin technology provides an immune-protected local environment for transplanted therapeutic cells such as insulin producing islets. The Company’s Cell Pouch system combined with its Sertolin immune protection technology offers therapeutic cells local protection from immune system attack creating an effective, safe, long-term and convenient therapeutic option for patients with chronic disease.

Officers and directors

Frank A. Holler Chairman of the Board
Age: 57
Philip Toleikis President, Chief Executive Officer, Director
Ralph Deiterding CPA Chief Financial Officer
James T. Parsons Director
Bruce Weber Director
Jeffrey A. Bacha Independent Director